MariMed Inc. (OTCMKTS:MRMD – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 1,000 shares, a decline of 97.8% from the September 15th total of 44,669 shares. Based on an average trading volume of 1,661,239 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are short sold.
MariMed Trading Down 0.3%
OTCMKTS MRMD traded down $0.00 on Friday, hitting $0.06. The company’s stock had a trading volume of 192,523 shares, compared to its average volume of 715,688. The company’s 50-day moving average is $0.07 and its 200 day moving average is $0.07. The firm has a market cap of $25.55 million, a PE ratio of -1.58 and a beta of 1.39. MariMed has a 1-year low of $0.06 and a 1-year high of $0.18. The company has a quick ratio of 0.34, a current ratio of 0.92 and a debt-to-equity ratio of 1.78.
MariMed (OTCMKTS:MRMD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $41.92 million for the quarter, compared to analyst estimates of $39.80 million. MariMed had a negative net margin of 9.13% and a negative return on equity of 10.71%.
MariMed Company Profile
MariMed, Inc is a U.S.-based cannabis company that develops, operates, and manages state-licensed cannabis businesses. Its activities include cannabis cultivation, product manufacturing, wholesale distribution, and retail dispensary operations.
The company offers cannabis products such as flower, pre-rolls, concentrates, edibles, tinctures, and topical products. Its portfolio has included brands such as Betty’s Eddies, Nature’s Heritage, InHouse, and Kalm Fusion, which are distributed through MariMed-operated dispensaries and other licensed retail channels.
MariMed serves regulated cannabis markets in multiple states, including Massachusetts, Maryland, Delaware, and Ohio.
See Also
- Five stocks we like better than MariMed
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
